Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19 CAR-T Cell Infusion”

29 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 29 results

Testing effectiveness (Phase 2)UnknownNCT02081937
What this trial is testing

CART-19 Immunotherapy in Mantle Cell Lymphoma

Who this might be right for
Hematopoietic/Lymphoid CancerNon-hodgkin Lymphoma,B CellMantle Cell Lymphoma
Chinese PLA General Hospital 2
Testing effectiveness (Phase 2)UnknownNCT04846439
What this trial is testing

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Who this might be right for
Platelet Transfusion RefractorinessAcute Leukemia in Remission
The First Affiliated Hospital of Soochow University 20
Early research (Phase 1)Study completedNCT03144583
What this trial is testing

Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy

Who this might be right for
LeukemiaLymphoma
Sara V. Latorre 50
Early research (Phase 1)Looking for participantsNCT07066397
What this trial is testing

FIT-CD19-CAR-T Cells in R/R B-ALL

Who this might be right for
Acute Lymphoblastic Leukemia
TriArm Therapeutics (Taiwan) Limited 12
Testing effectiveness (Phase 2)Looking for participantsNCT06364423
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellB-Lymphocytic Leukemia, ChronicB-Cell Chronic Lymphocytic Leukemia+4 more
National Cancer Institute (NCI) 132
Not applicableUnknownNCT04237428
What this trial is testing

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 20
Early research (Phase 1)UnknownNCT06212154
What this trial is testing

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Who this might be right for
Autoimmune Hemolytic AnemiaCD19 CAR-T Cell Infusion
Institute of Hematology & Blood Diseases Hospital, China 13
Testing effectiveness (Phase 2)UnknownNCT03207178
What this trial is testing

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Who this might be right for
Recurrent or Refractory B Cell Malignancy
Shanghai Longyao Biotechnology Inc., Ltd. 20
Very early researchLooking for participantsNCT06375161
What this trial is testing

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

Who this might be right for
B Cell Malignancies
Shanghai Tongji Hospital, Tongji University School of Medicine 12
Testing effectiveness (Phase 2)Looking for participantsNCT06350110
What this trial is testing

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus ErythematosusLupus NephritisAutoimmune Diseases+6 more
Essen Biotech 75
Early research (Phase 1)UnknownNCT05420493
What this trial is testing

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd 54
Early research (Phase 1)Ended earlyNCT04160195
What this trial is testing

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkinsChronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI) 2
Early research (Phase 1)Not Yet RecruitingNCT07491263
What this trial is testing

Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia

Who this might be right for
Relapsed/Refractory CD19-positive B-ALL
Fujian Medical University 6
Not applicableActive Not RecruitingNCT07101913
What this trial is testing

Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

Who this might be right for
Acute Kidney Injury (AKI)Infusion of CD19 CAR T CellB Cell Lymphoma
Hospices Civils de Lyon 300
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Early research (Phase 1)UnknownNCT04194931
What this trial is testing

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University 20
Early research (Phase 1)WithdrawnNCT04556266
What this trial is testing

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Who this might be right for
LeukemiaLymphomaLymphoma, B-Cell
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06902012
What this trial is testing

Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Zhujiang Hospital 15
Early research (Phase 1)Study completedNCT02659943
What this trial is testing

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkins
National Cancer Institute (NCI) 27
Load More Results